Cullinan Net Interest Income from 2010 to 2024

CGEM Stock  USD 23.46  0.52  2.17%   
Cullinan Oncology Net Interest Income yearly trend continues to be very stable with very little volatility. Net Interest Income is likely to grow to about 22.7 M this year. Net Interest Income is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. View All Fundamentals
 
Net Interest Income  
First Reported
2010-12-31
Previous Quarter
21.6 M
Current Value
22.7 M
Quarterly Volatility
7.6 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Cullinan Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cullinan main balance sheet or income statement drivers, such as Interest Expense of 679 M, Selling General Administrative of 44.6 M or Total Revenue of 0.0, as well as many exotic indicators such as Price To Sales Ratio of 28.86, Dividend Yield of 0.0 or PTB Ratio of 0.98. Cullinan financial statements analysis is a perfect complement when working with Cullinan Oncology Valuation or Volatility modules.
  
This module can also supplement Cullinan Oncology's financial leverage analysis and stock options assessment as well as various Cullinan Oncology Technical models . Check out the analysis of Cullinan Oncology Correlation against competitors.

Latest Cullinan Oncology's Net Interest Income Growth Pattern

Below is the plot of the Net Interest Income of Cullinan Oncology LLC over the last few years. It is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. Cullinan Oncology's Net Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cullinan Oncology's overall financial position and show how it may be relating to other accounts over time.
Net Interest Income10 Years Trend
Slightly volatile
   Net Interest Income   
       Timeline  

Cullinan Net Interest Income Regression Statistics

Arithmetic Mean3,766,957
Geometric Mean900,864
Coefficient Of Variation202.80
Mean Deviation5,286,064
Median397,000
Standard Deviation7,639,517
Sample Variance58.4T
Range22.3M
R-Value0.66
Mean Square Error35.3T
R-Squared0.44
Significance0.01
Slope1,131,673
Total Sum of Squares817.1T

Cullinan Net Interest Income History

202422.7 M
202321.6 M
20226.6 M
2021477 K
2020888 K
2019620 K

About Cullinan Oncology Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Cullinan Oncology income statement, its balance sheet, and the statement of cash flows. Cullinan Oncology investors use historical funamental indicators, such as Cullinan Oncology's Net Interest Income, to determine how well the company is positioned to perform in the future. Although Cullinan Oncology investors may use each financial statement separately, they are all related. The changes in Cullinan Oncology's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Cullinan Oncology's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Cullinan Oncology Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Cullinan Oncology. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Interest Income21.6 M22.7 M

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Cullinan Oncology LLC using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
When determining whether Cullinan Oncology LLC is a strong investment it is important to analyze Cullinan Oncology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cullinan Oncology's future performance. For an informed investment choice regarding Cullinan Stock, refer to the following important reports:
Check out the analysis of Cullinan Oncology Correlation against competitors.
Note that the Cullinan Oncology LLC information on this page should be used as a complementary analysis to other Cullinan Oncology's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Complementary Tools for Cullinan Stock analysis

When running Cullinan Oncology's price analysis, check to measure Cullinan Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cullinan Oncology is operating at the current time. Most of Cullinan Oncology's value examination focuses on studying past and present price action to predict the probability of Cullinan Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cullinan Oncology's price. Additionally, you may evaluate how the addition of Cullinan Oncology to your portfolios can decrease your overall portfolio volatility.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Is Cullinan Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.13)
Return On Assets
(0.22)
Return On Equity
(0.29)
The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.